- Home
- DUO vs AIM Comparison
DUO vs AIM Comparison
Compare DUO & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DUO
- AIM
- Stock Information
- Founded
- DUO 2011
- AIM 1966
- Country
- DUO China
- AIM United States
- Employees
- DUO N/A
- AIM N/A
- Industry
- DUO Real Estate
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DUO Finance
- AIM Health Care
- Exchange
- DUO Nasdaq
- AIM Nasdaq
- Market Cap
- DUO 14.6M
- AIM 15.9M
- IPO Year
- DUO 2019
- AIM N/A
- Fundamental
- Price
- DUO $0.69
- AIM $0.20
- Analyst Decision
- DUO
- AIM Strong Buy
- Analyst Count
- DUO 0
- AIM 2
- Target Price
- DUO N/A
- AIM $2.75
- AVG Volume (30 Days)
- DUO 17.2M
- AIM 403.8K
- Earning Date
- DUO 08-30-2024
- AIM 11-15-2024
- Dividend Yield
- DUO N/A
- AIM N/A
- EPS Growth
- DUO N/A
- AIM N/A
- EPS
- DUO N/A
- AIM N/A
- Revenue
- DUO $37,352,654.00
- AIM $190,000.00
- Revenue This Year
- DUO N/A
- AIM N/A
- Revenue Next Year
- DUO N/A
- AIM $1,086.80
- P/E Ratio
- DUO N/A
- AIM N/A
- Revenue Growth
- DUO 6.61
- AIM N/A
- 52 Week Low
- DUO $0.32
- AIM $0.16
- 52 Week High
- DUO $4.67
- AIM $0.62
- Technical
- Relative Strength Index (RSI)
- DUO 46.11
- AIM 40.44
- Support Level
- DUO $0.67
- AIM $0.20
- Resistance Level
- DUO $0.81
- AIM $0.23
- Average True Range (ATR)
- DUO 0.14
- AIM 0.02
- MACD
- DUO 0.03
- AIM 0.00
- Stochastic Oscillator
- DUO 15.19
- AIM 10.75
About DUO Fangdd Network Group Ltd.
Fangdd Network Group Ltd is an investment holding company. Through its subsidiaries, It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.